Stammdaten
Unternehmen
| Name | Xeris Biopharma Holdings, Inc. |
|---|---|
| Ticker | XERS |
| CIK | 0001867096 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Titel | Xeris Biopharma Holdings, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:36:35.143221 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,567 | 6.24 | -103,379.74 | -37,1% | |
| 2026-03-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -100 | 7.06 | -706.00 | -0,3% | |
| 2026-02-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.45 | -124,147.48 | -44,5% | |
| 2026-01-08 | McCulloch Kevin | Officer, See Remarks | Open Market Sale | -15,000 | 8.00 | -120,000.00 | -43,0% | |
| 2026-01-08 | McCulloch Kevin | Officer, See Remarks | Open Market Sale | -15,000 | 8.00 | -120,000.00 | -43,0% | |
| 2026-01-08 | McCulloch Kevin | Officer, See Remarks | Open Market Sale | -15,000 | 8.00 | -120,000.00 | -43,0% | |
| 2026-01-05 | Shannon John Patrick Jr | Director, Officer, See Remarks | Open Market Sale | -24,907 | 7.08 | -176,256.88 | -63,2% | |
| 2026-01-02 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.43 | -123,775.81 | -44,4% | |
| 2025-12-19 | JOHNSON JOHN | Director | Open Market Sale | -135,400 | 7.22 | -977,019.32 | -350,2% | |
| 2025-12-19 | JOHNSON JOHN | Director | Open Market Sale | -135,400 | 7.22 | -977,019.32 | -350,2% | |
| 2025-12-12 | BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | Open Market Sale | -15,000 | 7.09 | -106,414.50 | -38,1% | |
| 2025-12-01 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.01 | -116,780.67 | -41,9% | |
| 2025-11-13 | Shannon John Patrick Jr | Director, Officer, See Remarks | Open Market Sale | -23,242 | 7.46 | -173,401.59 | -62,2% | |
| 2025-11-11 | Hecht Beth | Officer, See Remarks | Open Market Sale | -16,667 | 7.40 | -123,295.80 | -44,2% | |
| 2025-09-11 | PERSKY MARLA | Director | Open Market Sale | -15,500 | 7.72 | -119,610.40 | -42,9% | |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Open Market Sale | -42,232 | 7.92 | -334,515.45 | -119,9% | |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Open Market Sale | -42,232 | 7.92 | -334,515.45 | -119,9% | |
| 2025-08-28 | SHERMAN JEFFREY W | Director | Open Market Sale | -42,232 | 7.92 | -334,515.45 | -119,9% | |
| 2025-08-13 | JOHNSON JOHN | Director | Open Market Sale | -107,500 | 7.32 | -786,459.25 | -281,9% | |
| 2025-08-13 | JOHNSON JOHN | Director | Open Market Sale | -107,500 | 7.32 | -786,459.25 | -281,9% | |
| 2025-08-12 | HALKUFF DAWN | Director | Open Market Sale | -42,500 | 7.28 | -309,225.75 | -110,8% | |
| 2025-06-13 | McCulloch Kevin | Officer, See Remarks | Open Market Purchase | 25,000 | 4.38 | 109,475.00 | +39,2% | |
| 2025-06-13 | McCulloch Kevin | Officer, See Remarks | Open Market Purchase | 25,000 | 4.38 | 109,475.00 | +39,2% | |
| 2025-06-13 | McCulloch Kevin | Officer, See Remarks | Open Market Purchase | 25,000 | 4.38 | 109,475.00 | +39,2% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.